Arcturus Therapeutics Holdings Financial Statements (ARCT)
|
|
|
|
Report date
|
|
|
01.03.2022 |
29.03.2023 |
14.03.2024 |
06.03.2025 |
03.03.2026 |
|
07.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
12.4 |
205.8 |
157.7 |
138.4 |
67.2 |
|
45.4 |
|
Operating Income, bln rub |
|
|
-202.9 |
12.2 |
-78.2 |
-95.7 |
-75.0 |
|
-89.2 |
|
EBITDA, bln rub |
? |
|
-201.7 |
13.7 |
-24.2 |
-77.4 |
-62.8 |
|
-72.8 |
|
Net profit, bln rub |
? |
|
-203.7 |
9.35 |
-29.7 |
-80.9 |
-65.8 |
|
-78.7 |
|
|
OCF, bln rub |
? |
|
-135.0 |
32.0 |
-18.1 |
-59.7 |
-74.3 |
|
-58.6 |
|
CAPEX, bln rub |
? |
|
3.41 |
7.73 |
2.90 |
0.648 |
0.230 |
|
0.319 |
|
FCF, bln rub |
? |
|
-138.4 |
24.3 |
-21.0 |
-60.4 |
-74.3 |
|
-58.9 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
215.2 |
193.6 |
236.0 |
234.1 |
139.2 |
|
130.6 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
3.03 |
|
4.00 |
|
R&D, bln rub |
|
|
173.8 |
147.8 |
192.1 |
195.2 |
112.2 |
|
98.2 |
|
Interest expenses, bln rub |
|
|
2.67 |
3.00 |
0.767 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
392.8 |
450.4 |
429.4 |
344.1 |
271.1 |
|
245.4 |
|
Net Assets, bln rub |
? |
|
228.2 |
270.3 |
278.5 |
241.0 |
214.0 |
|
191.4 |
|
Debt, bln rub |
|
|
69.1 |
94.8 |
30.2 |
28.6 |
25.0 |
|
19.7 |
|
Cash, bln rub |
|
|
370.5 |
391.9 |
292.0 |
237.0 |
230.9 |
|
211.4 |
|
Net debt, bln rub |
|
|
-301.3 |
-297.1 |
-261.8 |
-208.5 |
-205.9 |
|
-191.7 |
|
|
Ordinary share price, rub |
|
|
37.0 |
|
|
17.0 |
6.13 |
|
7.53 |
|
Number of ordinary shares, mln |
|
|
26.3 |
26.4 |
26.6 |
27.0 |
27.4 |
|
28.4 |
|
|
Market cap, bln rub |
|
|
974 |
0 |
0 |
458 |
168 |
|
214 |
|
EV, bln rub |
? |
|
673 |
-297 |
-262 |
250 |
-38 |
|
22 |
|
Book value, bln rub |
|
|
228 |
270 |
279 |
241 |
214 |
|
191 |
|
|
EPS, rub |
? |
|
-7.74 |
0.35 |
-1.12 |
-3.00 |
-2.40 |
|
-2.77 |
|
FCF/share, rub |
|
|
-5.26 |
0.92 |
-0.79 |
-2.24 |
-2.71 |
|
-2.07 |
|
BV/share, rub |
|
|
8.67 |
10.2 |
10.5 |
8.93 |
7.81 |
|
6.73 |
|
|
EBITDA margin, % |
? |
|
-1 632% |
6.66% |
-15.3% |
-55.9% |
-93.4% |
|
-160.5% |
|
Net margin, % |
? |
|
-1 648% |
4.54% |
-18.8% |
-58.5% |
-97.9% |
|
-173.5% |
|
FCF yield, % |
? |
|
-14.2% |
|
|
-13.2% |
-44.2% |
|
-27.5% |
|
ROE, % |
? |
|
-89.2% |
3.46% |
-10.7% |
-33.6% |
-30.7% |
|
-41.1% |
|
ROA, % |
? |
|
-51.8% |
2.08% |
-6.92% |
-23.5% |
-24.3% |
|
-32.1% |
|
|
P/E |
? |
|
-4.78 |
0.00 |
0.00 |
-5.66 |
-2.55 |
|
-2.72 |
|
P/FCF |
|
|
-7.04 |
0.00 |
0.00 |
-7.59 |
-2.26 |
|
-3.63 |
|
P/S |
? |
|
78.8 |
0.00 |
0.00 |
3.31 |
2.50 |
|
4.72 |
|
P/BV |
? |
|
4.27 |
0.00 |
0.00 |
1.90 |
0.78 |
|
1.12 |
|
EV/EBITDA |
? |
|
-3.34 |
-21.7 |
10.8 |
-3.23 |
0.61 |
|
-0.31 |
|
Debt/EBITDA |
|
|
1.49 |
-21.7 |
10.8 |
2.69 |
3.28 |
|
2.63 |
|
|
R&D/CAPEX, % |
|
|
5 102% |
1 912% |
6 623% |
30 117% |
48 788% |
|
30 831% |
|
|
CAPEX/Revenue, % |
|
|
27.6% |
3.75% |
1.84% |
0.47% |
0.34% |
|
0.70% |
|
| Arcturus Therapeutics Holdings shareholders |
